Source:http://linkedlifedata.com/resource/pubmed/id/18729537
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
2008-8-27
|
pubmed:abstractText |
*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout. *In a randomized, double-blind, dose-ranging study in patients with gout and hyperuricaemia, significantly more recipients of febuxostat 40-120 mg/day than placebo had serum urate levels of < 6.0 mg/dL after 4 weeks of treatment. *Serum urate levels were reduced below 6.0 mg/dL at the last three monthly observations in a significantly greater proportion of patients with gout and hyperuricaemia receiving febuxostat 80 or 120 mg once daily than in those receiving allopurinol 300 mg once daily in a 52-week, randomized, double-blind trial (FACT). *Similarly, febuxostat 80, 120 or 240 mg once daily showed significantly greater urate-lowering efficacy than allopurinol 100 or 300 mg once daily in a 28-week, randomized, double-blind, placebo-controlled trial (APEX) in patients with gout and hyperuricaemia. *Long-term treatment with febuxostat for up to 4 years or more reduced the incidence of gout flares to (or close to) zero. *Febuxostat was generally well tolerated in clinical trials, including extension studies lasting > or = 4 years, with most treatment-related adverse events being mild to moderate in severity.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0012-6667
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1865-74
|
pubmed:meshHeading |
pubmed-meshheading:18729537-Administration, Oral,
pubmed-meshheading:18729537-Gout,
pubmed-meshheading:18729537-Gout Suppressants,
pubmed-meshheading:18729537-Humans,
pubmed-meshheading:18729537-Hyperuricemia,
pubmed-meshheading:18729537-Molecular Structure,
pubmed-meshheading:18729537-Randomized Controlled Trials as Topic,
pubmed-meshheading:18729537-Thiazoles,
pubmed-meshheading:18729537-Treatment Outcome,
pubmed-meshheading:18729537-Uric Acid
|
pubmed:year |
2008
|
pubmed:articleTitle |
Febuxostat.
|
pubmed:affiliation |
Wolters Kluwer Health | Adis, Auckland, New Zealand.
|
pubmed:publicationType |
Journal Article,
Review
|